Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2017
At a glance
- Drugs ALT 803 (Primary) ; Natural killer cell therapy (Primary)
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Colon cancer; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Soft tissue sarcoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned number of patients changed from 27 to 54.
- 30 Mar 2017 Planned initiation date changed from 1 Oct 2016 to 1 May 2017.